Intec Pharma Ltd. (NTEC) financial statements (2022 and earlier)

Company profile

Business Address 12 HARTOM STREET
JERUSALEM, 777512
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 10,06240,579
Cash and cash equivalents 9,29239,246
Short-term investments 7701,333
Receivables 3,6832,986
Total current assets: 13,74543,565
Noncurrent Assets
Operating lease, right-of-use asset 1,243
Property, plant and equipment 2,57512,233
Other noncurrent assets 3,7175,431
Other undisclosed noncurrent assets  281
Total noncurrent assets: 7,53517,945
TOTAL ASSETS: 21,28061,510
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including: 4,8354,807
Accounts payable 2220
Accrued liabilities 2,8383,400
Employee-related liabilities 1,4311,387
Other undisclosed accounts payable and accrued liabilities 544 
Other undisclosed current liabilities 3,5072,849
Total current liabilities: 8,3427,656
Noncurrent Liabilities
Long-term debt and lease obligation 799 
Operating lease, liability 799
Liabilities, other than long-term debt 604309
Other liabilities 604309
Total noncurrent liabilities: 1,403309
Total liabilities: 9,7457,965
Stockholders' equity
Stockholders' equity attributable to parent 11,53553,545
Common stock 727727
Additional paid in capital 200,231194,642
Accumulated deficit (189,423)(141,824)
Total stockholders' equity: 11,53553,545
TOTAL LIABILITIES AND EQUITY: 21,28061,510

Income statement (P&L) ($ in thousands)

12/31/2020
12/31/2019
12/31/2018
Revenues 1,500852
Net investment income  852
Other income 1,500 
Gross profit: 1,500852
Operating expenses (48,609)(43,328)
Other undisclosed operating loss  (852)
Operating loss: (47,109)(43,328)
Loss from continuing operations before equity method investments, income taxes: (47,109)(43,328)
Other undisclosed income (loss) from continuing operations before income taxes 148(112)
Loss from continuing operations before income taxes: (46,961)(43,440)
Income tax expense (638)(103)
Net loss available to common stockholders, diluted: (47,599)(43,543)

Comprehensive Income ($ in thousands)

12/31/2020
12/31/2019
12/31/2018
Net loss: (47,599)(43,543)
Comprehensive loss, net of tax, attributable to parent: (47,599)(43,543)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: